• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biochemistry (Mosc) . Development of a Platform for Producing Recombinant Protein Components of Epitope Vaccines for the Prevention of COVID-19

tetano

Editor, Senior Moderator
Biochemistry (Mosc)


. 2021 Oct;86(10):1275-1287.
doi: 10.1134/S0006297921100096.
Development of a Platform for Producing Recombinant Protein Components of Epitope Vaccines for the Prevention of COVID-19


Anna S Karyagina[SUP] 1 2 3 [/SUP], Alexander V Gromov[SUP] 4 [/SUP], Tatyana M Grunina[SUP] 4 2 [/SUP], Alexander M Lyaschuk[SUP] 4 [/SUP], Alexander V Grishin[SUP] 4 [/SUP], Natalia V Strukova[SUP] 4 [/SUP], Maria S Generalova[SUP] 4 [/SUP], Zoya M Galushkina[SUP] 4 [/SUP], Lyubov' A Soboleva[SUP] 4 [/SUP], Olga Yu Dobrinina[SUP] 4 [/SUP], Tatyana N Bolshakova[SUP] 4 [/SUP], Marina E Subbotina[SUP] 5 2 [/SUP], Ekaterina A Romanovskaya-Romanko[SUP] 6 [/SUP], Igor V Krasilnikov[SUP] 7 [/SUP], Nikita B Polyakov[SUP] 4 8 [/SUP], Andrey I Solovyev[SUP] 4 [/SUP], Daniil A Grumov[SUP] 4 [/SUP], Vladimir G Zhukhovitsky[SUP] 4 [/SUP], Ekaterina I Ryabova[SUP] 4 [/SUP], Vladimir V Prokofiev[SUP] 4 [/SUP], Vladimir G Lunin[SUP] 4 2 [/SUP]



Affiliations

Abstract

A new platform for creating anti-coronavirus epitope vaccines has been developed. Two loop-like epitopes with lengths of 22 and 42 amino acid residues were selected from the receptor-binding motif of the Spike protein from the SARS-CoV-2 virus that participate in a large number of protein-protein interactions in the complexes with ACE2 and neutralizing antibodies. Two types of hybrid proteins, including one of the two selected epitopes, were constructed. To fix conformation of the selected epitopes, an approach using protein scaffolds was used. The homologue of Rop protein from the Escherichia coli ColE1 plasmid containing helix-turn-helix motif was used as an epitope scaffold for the convergence of C- and N-termini of the loop-like epitopes. Loop epitopes were inserted into the turn region. The conformation was additionally fixed by a disulfide bond formed between the cysteine residues present within the epitopes. For the purpose of multimerization, either aldolase from Thermotoga maritima, which forms a trimer in solution, or alpha-helical trimerizer of the Spike protein from SARS-CoV-2, was attached to the epitopes incorporated into the Rop-like protein. To enable purification on the heparin-containing sorbents, a short fragment from the heparin-binding hemagglutinin of Mycobacterium tuberculosis was inserted at the C-terminus of the hybrid proteins. All the obtained proteins demonstrated high level of immunogenicity after triplicate parenteral administration to mice. Sera from the mice immunized with both aldolase-based hybrid proteins and the Spike protein SARS-CoV-2 trimerizer-based protein with a longer epitope interacted with both the inactivated SARS-CoV-2 virus and the Spike protein receptor-binding domain at high titers.

Keywords: RBD; RBM; SARS-CoV-2; Spike protein; aldolase; epitope; epitope scaffold; epitope vaccine; hybrid protein.
 
Back
Top Bottom